JS
JSPRW
Jasper Therapeutics, Inc.
$0.0142
-30.39%
$408.8K
No data for this timeframe.
Vol
Market Cap$408.8K
Cap SizeNano Cap
Inst. Holders1 funds
Inst. Value$4.00
Inst. Activity0 buys / 1 sells
SEC Reports4
Exchange Nasdaq·Sector Biological Products, (No Diagnostic Substances)·Inc. DE·CIK 0001788028·Prev Close $0.0204
Recent Activity
Jun 1, 2026
SEC
Jasper Therapeutics announced its Board has initiated a comprehensive review of strategic alternatives to maximize share
8-K — Impact 6/10
May 21, 2026
SEC
Jasper Therapeutics disclosed the resignation of board member Christian Nolet, effective May 15, 2026, citing no disagre
8-K — Impact 2/10
May 15, 2026
clinical_trial_readout
T-90d Trial Readout: Briquilimab (Phase 2)
Trial: A Phase 2, Open-Label, Extension Study to Evaluate Long Term Safety and Clinical Activity of
May 14, 2026
SEC
Jasper Therapeutics reported Q1 2026 results with a net loss of $1.2M ($0.04/share) vs $21.2M loss ($1.41/share) in Q1 2
8-K — Impact 6/10
Inst.
UBS Group AG — TRIM
1,304 shares ($133.00)
Latest Reports
BEARISH
8-K
6/10
Jasper Therapeutics announced its Board has initiated a comprehensive review of strategic alternatives to maximize share
Jun 1, 2026
NEUTRAL
8-K
2/10
Jasper Therapeutics disclosed the resignation of board member Christian Nolet, effective May 15, 2026, citing no disagre
May 21, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| BANK OF AMERICA CORP | $4.00 | — |
1 institutional holders with $4.00 total value (100 shares) as of 2025-Q4. Top holders: BANK.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | BANK OF AMERICA CORP /DE/ | 100 | $4.00 | 100.0% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| UBS Group AG | TRIM | 2,572 | 1,304 | -49.3% | $133.00 | 2025-Q1 |
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
4 SEC filing reports analyzed. Sentiment: 0 bullish, 2 bearish, 1 mixed, 1 neutral. Avg impact: 5.0/10.
BEARISH
8-K
6/10
Jasper Therapeutics announced its Board has initiated a comprehensive review of strategic alternativ
Jun 1, 2026
NEUTRAL
8-K
2/10
Jasper Therapeutics disclosed the resignation of board member Christian Nolet, effective May 15, 202
May 21, 2026
BEARISH
8-K
6/10
Jasper Therapeutics reported Q1 2026 results with a net loss of $1.2M ($0.04/share) vs $21.2M loss (
May 14, 2026
MIXED
8-K
6/10
Jasper Therapeutics reported Q4 and full-year 2025 financial results, highlighting positive clinical
Apr 21, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | 0.0% | — |
| Next Q 2026-09-30 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | 0.0% | — |
| Current FY 2026-12-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | 0.0% | — |
| Next FY 2027-12-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | 0.0% | — |
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 15, 2026
clinical_trial_readout
T-90d Trial Readout: Briquilimab (Phase 2)
Trial: A Phase 2, Open-Label, Extension Study to Evaluate Long Term Safety and Clinical Activity of Briquilimab in Participants From Jasper-Sponsored